8th Asia Dengue Summit Renews Call to Achieve Zero Dengue Deaths, with a Record 14 million Global Cases Reported in 2024
Health leaders, researchers, and advocates unite to advance efforts against dengue through innovation, prevention, and cross-sector collaboration. MANILA, Philippines, June 16, 2025 /PRNewswire/ -- As dengue cases in 2024 double to over 14 million globally, with Asia accounting for 70% of the global burden in 2024, the Asia Dengue Voice and Action (ADVA) Group reinforces the...
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed as treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC") CASTRES, France, June 16, 2025 /PRNewswire/ -- Pierre Fabre Laboratories are pleased to announce the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out...
Clarivate Identifies Radioligand Therapy Innovators as Companies to Watch in the Future of Precision Oncology
New Report Highlights Emerging Leaders Advancing Next-generation Radiopharmaceuticals, Reshaping Cancer Care Through Targeted Innovation and Strategic Growth LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, Radioligand Innovators Ushering in a New...
Leader Healthcare Implements SAP S/4HANA Public Cloud With Accely To Drive Operational Excellence
With SAP S/4HANA Public Cloud, the foremost healthcare equipment supplier in the UAE starts a digital transformation journey to improve the agility, efficiency, and innovation of its healthcare supply chain management. DUBAI, UAE, June 16, 2025 /PRNewswire/ -- In a strategic move to redefine operational excellence and accelerate digital transformation, UAE's healthcare equipment supplier, Leader Healthcare has successfully...
Hasten Accelerates Asia-Pacific Expansion with Successful MAT Transfers of 11 Products
SHANGHAI, June 16, 2025 /PRNewswire/ -- Hasten Biopharmaceutical Co., Ltd. ("Hasten") announced today the completion of Market Authorization Transfers (MAT) for 11 major pharmaceutical products across several key Asia-Pacific markets, including Malaysia, Singapore, Philippines, Hong Kong S.A.R. (China), etc.. The transfers were carried out by its affiliated entity, Hasten Biopharmaceutics (Asia) Co., Ltd., during the first half of...
The 4th Edition of AMSC Malaysia Returns in 2025: Uniting Global Leaders in Aesthetic Medicine, Dermatology, and Surgery
KUALA LUMPUR, Malaysia, June 16, 2025 /PRNewswire/ -- The Aesthetic Medicine & Surgery Conference & Exhibition (AMSC) returns for its highly anticipated fourth edition on 6–7 August 2025 at the prestigious Kuala Lumpur Convention Centre (KLCC). Speaker presenting advanced facial aesthetic techniques during AMSC 2024 Malaysia at KLCC, held on 20–21 September ...
Abbisko Therapeutics Completes First Patient Dosing in Registrational Study of Irpagratinib for HCC
SHANGHAI, June 16, 2025 /PRNewswire/ -- Abbisko Therapeutics (HKEX Code: 02256) today announced that it has completed first patient dosing in a registrational study of irpagratinib, a self-developed and highly-selective small molecule FGFR4 inhibitor, for the treatment of Hepatocellular Carcinoma (HCC). In May, irpagratinib received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China's National Medical...
SDP Japan Raises $31 Million in Series D Round
Pioneering the Future of Surgical Care in Response to Rising Demand TOKYO, June 16, 2025 /PRNewswire/ -- SDP Japan, Inc. (Shibuya-ku, Tokyo; CEO: Kazuhiko Nagayo), announced today that the Company has successfully raised approximately JPY 4.5 billion (equivalent to USD 31 million) through a Series D equity financing round, alongside secondary transaction, debt financing and asset-based funding....
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
HONG KONG, June 16, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or metastatic cervical cancer. The data was featured as an oral presentation at the 2025 American Society of Clinical...
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the National Medical Products Administration (NMPA) has officially accepted its New Drug Application (NDA) for Azstarys (serdexmethylphenidate/dexmethylphenidate extended-release capsules) and granted it Priority Review designation. The investigational therapeutic drug is indicated for the treatment of Attention-Deficit/Hyperactivity...
